Nothing Special   »   [go: up one dir, main page]

CR20170033A - Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso. - Google Patents

Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso.

Info

Publication number
CR20170033A
CR20170033A CR20170033A CR20170033A CR20170033A CR 20170033 A CR20170033 A CR 20170033A CR 20170033 A CR20170033 A CR 20170033A CR 20170033 A CR20170033 A CR 20170033A CR 20170033 A CR20170033 A CR 20170033A
Authority
CR
Costa Rica
Prior art keywords
monoclonal antibody
pharmaceutical composition
antigen binding
binding fragment
ctla4 monoclonal
Prior art date
Application number
CR20170033A
Other languages
English (en)
Inventor
Baiyong Li
Zhongmin Wang
Yu Xia
Xinghua Pang
Peng; Zhang
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Publication of CR20170033A publication Critical patent/CR20170033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención pertenece a los campos de terapia tumoral e inmunología molecular, y proporciona un anticuerpo monoclonal anti-CTLA4 o fragmento de unión a antígeno del mismo, una composición farmacéutica del mismo y su uso; el anticuerpo monoclonal de la presente invención puede bloquear la unión de CLTA4 a B7, aliviar la inmunosupresión en el cuerpo por CTLA4 y activar los linfocitos T.
CR20170033A 2014-08-01 2015-08-31 Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso. CR20170033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410377352.9A CN105296433B (zh) 2014-08-01 2014-08-01 一种ctla4抗体、其药物组合物及其用途
PCT/CN2015/085721 WO2016015675A1 (zh) 2014-08-01 2015-07-31 抗ctla4的单克隆抗体或其抗原结合片段、药物组合物及用途

Publications (1)

Publication Number Publication Date
CR20170033A true CR20170033A (es) 2017-09-29

Family

ID=55194268

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170033A CR20170033A (es) 2014-08-01 2015-08-31 Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso.

Country Status (39)

Country Link
US (3) US10449251B2 (es)
EP (2) EP3176181B1 (es)
JP (2) JP6514774B2 (es)
KR (1) KR102017396B1 (es)
CN (3) CN105296433B (es)
AP (1) AP2017009762A0 (es)
AU (2) AU2015295936C1 (es)
CA (1) CA2956000C (es)
CL (1) CL2017000250A1 (es)
CO (1) CO2017000754A2 (es)
CR (1) CR20170033A (es)
CY (1) CY1124190T1 (es)
DK (1) DK3176181T3 (es)
DO (1) DOP2017000031A (es)
EA (1) EA036396B1 (es)
EC (1) ECSP17012781A (es)
ES (1) ES2857509T3 (es)
GE (1) GEP20207166B (es)
HR (1) HRP20210448T1 (es)
HU (1) HUE053719T2 (es)
IL (1) IL250321B (es)
LT (1) LT3176181T (es)
MA (2) MA40474B1 (es)
MD (1) MD4795C1 (es)
MX (2) MX2017001446A (es)
MY (1) MY192822A (es)
NI (1) NI201700008A (es)
NZ (1) NZ729158A (es)
PE (1) PE20170772A1 (es)
PH (1) PH12017500190A1 (es)
PL (1) PL3176181T3 (es)
PT (1) PT3176181T (es)
RS (1) RS61590B1 (es)
SG (1) SG11201700819QA (es)
SI (1) SI3176181T1 (es)
TN (1) TN2017000010A1 (es)
UA (1) UA119570C2 (es)
WO (1) WO2016015675A1 (es)
ZA (1) ZA201700528B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
SG10201913276WA (en) 2015-09-01 2020-02-27 Agenus Inc Anti-pd-1 antibodies and methods of use thereof
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
EP3433275A1 (en) 2016-03-24 2019-01-30 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
CA3026477A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
JP6976322B2 (ja) * 2016-10-10 2021-12-08 クラウン バイオサイエンス，インコーポレイテッド（タイツァン） 新規抗ｃｔｌａ４抗体
MX2019003683A (es) 2016-10-11 2019-08-22 Agenus Inc Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
MX2019006340A (es) 2016-12-07 2019-11-07 Agenus Inc Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
EP3597735A4 (en) * 2017-03-15 2020-11-25 Suzhou Galaxy Biopharma, Co., Ltd. CTLA4 ANTIBODIES, PHARMACEUTICAL COMPOSITION AND USES THEREOF
US20200115451A1 (en) * 2017-03-31 2020-04-16 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody
CA3060695A1 (en) * 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3060581A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN108948194B (zh) * 2017-05-19 2023-02-17 上海药明生物技术有限公司 一种新的ctla-4单克隆抗体
IL312337A (en) 2017-05-19 2024-06-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), preparations containing them and uses thereof
CN107325181A (zh) * 2017-07-05 2017-11-07 无锡傲锐东源生物科技有限公司 抗ctla4蛋白单克隆抗体及其用途
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
WO2019056281A1 (en) * 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd ANTI-CTLA4 ANTIBODIES AND USES THEREOF
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
BR112020015915A8 (pt) * 2018-02-13 2023-01-31 Merck Sharp & Dohme Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
WO2019179388A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-ctla-4 antibody polypeptide
CN109336975B (zh) * 2018-04-18 2022-05-13 中国科学院微生物研究所 一种靶向pd-1的肿瘤抑制性抗体及其应用
CN112399973B (zh) 2018-06-05 2022-12-16 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
CN110760002A (zh) * 2018-07-25 2020-02-07 南京金斯瑞生物科技有限公司 人源化抗人ctla4单克隆抗体及其制备方法和用途
AU2019407814A1 (en) 2018-12-21 2021-07-22 Boehringer Ingelheim International Gmbh Bifunctional anti-PD-1/IL-7 molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
CN110256561B (zh) * 2019-06-13 2021-04-16 东大生物技术(苏州)有限公司 一组ctla-4单克隆抗体及其医药用途
CN110256563A (zh) * 2019-07-05 2019-09-20 石河子大学 Ctla-4纳米抗体、制备方法及其应用
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4114863A4 (en) * 2020-03-05 2024-04-24 Merck Sharp & Dohme LLC METHODS OF TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY AND AN ANTI-TIGIT ANTIBODY
WO2021208838A1 (en) * 2020-04-13 2021-10-21 Biosion Inc. Antibodies binding ctla4 and uses thereof
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
CN113980130B (zh) * 2020-07-27 2023-07-21 湖南远泰生物技术有限公司 人源化cd37和双特异性cd19-人源化cd37 car-t细胞
CN112079926A (zh) * 2020-09-17 2020-12-15 北京华大蛋白质研发中心有限公司 抗人ctla4单克隆抗体及其应用
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
WO2022214653A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN114316053B (zh) * 2021-12-20 2023-09-29 南京诺唯赞检测技术有限公司 一种vce的单克隆抗体及其制备方法
CN118541390A (zh) * 2022-01-30 2024-08-23 百奥赛图(北京)医药科技股份有限公司 抗ctla4/ox40双特异性抗体及其用途
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
TW202426499A (zh) * 2022-09-16 2024-07-01 大陸商同潤生物醫藥(上海)有限公司 具有pH依賴性的抗CTLA4抗體或抗原結合片段
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US682736A (en) 1900-08-02 1901-09-17 James C Owen Oil-can.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
NZ306304A (en) 1995-04-27 1999-03-29 Advanced Tissue Sciences Inc Apparatus and method for sterilizing, seeding, culturing, storing, shipping and testing tissue, synthetic or native vascular grafts
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US7122615B1 (en) 1998-09-10 2006-10-17 Rutgers, The State University Of New Jersey Polyanhydrides with therapeutically useful degradation products
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
BRPI9916853B8 (pt) 1998-12-23 2021-05-25 Abgenix Inc anticorpo monoclonal ou um fragmento de ligação a antígeno do mesmo que se liga especificamente ao antígeno do linfócito t citotóxico 4 (ctla-4) e ácido nucleico
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
CA2481207C (en) 2002-04-12 2015-06-30 Medarex, Inc. Methods of treatment using ctla-4 antibodies
EP2484660A3 (en) 2002-05-24 2013-03-13 Castrol Limited Preparation of monomers for grafting to polyolefins
DK2206517T3 (da) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer
AU2003260871A1 (en) 2002-09-30 2004-04-19 Pfizer Products Inc. Hybridomas producing high levels of human sequence antibody
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
CN1964739A (zh) 2004-03-26 2007-05-16 辉瑞产品公司 抗ctla－4抗体的用途
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
CA2600608A1 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising human igg2 antibody and chelating agent
WO2006110277A1 (en) 2005-04-11 2006-10-19 Medarex, Inc. Protein purification using hcic amd ion exchange chromatography
EP2161336B2 (en) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
CN101074264B (zh) * 2006-05-17 2011-08-17 上海抗体药物国家工程研究中心有限公司 一种重组抗ctla4单克隆抗体及其制备方法和用途
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CA2777226A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
NO2501822T3 (es) 2009-11-17 2018-01-13
CN102134276A (zh) * 2010-01-22 2011-07-27 上海抗体药物国家工程研究中心有限公司 一种抗ctla-4嵌合抗体
CN103221544A (zh) * 2010-09-24 2013-07-24 昂克斯治疗有限公司 编码单克隆抗-ctla-4抗体的溶瘤腺病毒载体
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
RU2657440C2 (ru) 2011-06-30 2018-06-13 Джензим Корпорейшн Ингибиторы т-клеточной активации
WO2013142796A2 (en) 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US8844207B2 (en) 2012-06-04 2014-09-30 Mity-Lite, Inc. Portable dance floor panel with floating magnet retention system
CN102801616B (zh) 2012-08-02 2015-04-15 华为技术有限公司 报文发送和接收的方法、装置和系统
EP2759305A1 (en) 2013-01-24 2014-07-30 Thrombotargets Europe, S.L. Hemostatic compositions
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
KR20160119867A (ko) 2014-03-05 2016-10-14 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
MX2016014753A (es) 2014-05-15 2017-03-06 Bristol Myers Squibb Co Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno.
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
MX2017007390A (es) 2014-12-16 2017-11-06 Bristol Myers Squibb Co Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales.
CN104479019B (zh) 2014-12-26 2020-07-21 上海复宏汉霖生物技术股份有限公司 一种抗ctla-4人源抗体
SG10202006863YA (en) 2015-02-16 2020-08-28 Lonza Ag Cl and/or ch1 mutated antibodies for drug conjugation
US20180256715A1 (en) 2015-05-13 2018-09-13 The Board Of Regents Of The University Of Texas System Anti-ctla-4 blockade
JP2019503387A (ja) 2016-01-27 2019-02-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および別の抗癌剤の組合せを用いる肺癌の処置法

Also Published As

Publication number Publication date
NZ729158A (en) 2020-03-27
PL3176181T3 (pl) 2021-07-26
PE20170772A1 (es) 2017-07-04
MD4795B1 (ro) 2022-02-28
MD20170022A2 (ro) 2017-06-30
UA119570C2 (uk) 2019-07-10
AP2017009762A0 (en) 2017-02-28
AU2015295936B2 (en) 2018-11-08
CN106687479B (zh) 2022-10-25
US20170216433A1 (en) 2017-08-03
US11291720B2 (en) 2022-04-05
KR102017396B1 (ko) 2019-09-02
CL2017000250A1 (es) 2017-08-18
MX2021013586A (es) 2021-12-10
HUE053719T2 (hu) 2021-07-28
DK3176181T3 (da) 2021-03-08
US20200206346A1 (en) 2020-07-02
AU2015295936A1 (en) 2017-03-09
NI201700008A (es) 2017-03-08
GEP20207166B (en) 2020-10-12
IL250321A0 (en) 2017-03-30
CN106687479A8 (zh) 2017-07-07
EP3176181A4 (en) 2018-03-14
SG11201700819QA (en) 2017-03-30
MA40474A (fr) 2017-06-07
ZA201700528B (en) 2022-11-30
EP3176181A1 (en) 2017-06-07
AU2018247270A1 (en) 2018-11-01
EA036396B1 (ru) 2020-11-05
EP3858861A1 (en) 2021-08-04
BR112017002080A2 (pt) 2018-02-27
CY1124190T1 (el) 2022-05-27
TN2017000010A1 (en) 2018-07-04
SI3176181T1 (sl) 2021-07-30
ES2857509T3 (es) 2021-09-29
JP6514774B2 (ja) 2019-05-15
JP6783886B2 (ja) 2020-11-11
DOP2017000031A (es) 2017-07-15
CA2956000A1 (en) 2016-02-04
HRP20210448T1 (hr) 2021-05-28
JP2019107018A (ja) 2019-07-04
EA201790288A1 (ru) 2017-06-30
CN115960232A (zh) 2023-04-14
CN106687479A (zh) 2017-05-17
US20230064544A1 (en) 2023-03-02
PH12017500190A1 (en) 2017-06-28
PT3176181T (pt) 2021-03-04
AU2015295936C1 (en) 2019-08-01
MX2017001446A (es) 2017-12-15
CN105296433B (zh) 2018-02-09
EP3176181B1 (en) 2020-12-23
WO2016015675A1 (zh) 2016-02-04
RS61590B1 (sr) 2021-04-29
IL250321B (en) 2021-06-30
ECSP17012781A (es) 2017-08-31
KR20170036092A (ko) 2017-03-31
MA55868A (fr) 2022-04-06
MD4795C1 (ro) 2022-09-30
JP2017523807A (ja) 2017-08-24
MA40474B1 (fr) 2021-02-26
MY192822A (en) 2022-09-12
LT3176181T (lt) 2021-04-12
US10449251B2 (en) 2019-10-22
CA2956000C (en) 2022-09-27
CO2017000754A2 (es) 2017-06-30
CN105296433A (zh) 2016-02-03

Similar Documents

Publication Publication Date Title
DOP2017000031A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CL2017001217A1 (es) Conjugados de droga de anticuerpos.
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PE20190737A1 (es) Anticuerpos anti-cd27
EA201591801A1 (ru) Лекарственные конъюгаты антител
UY35965A (es) Anticuerpos humanos contra pd?l1
CR20170059A (es) ANTICUERPOS Anti-LAG3 Y FRAGMENTOS DE UNIÓN A ANTÍGENO
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
EA201791049A1 (ru) Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы)
AR110106A1 (es) Inmunoglobulinas y usos de estas
AR107223A1 (es) Anticuerpos dirigidos contra upk1b y métodos para su uso
AR102495A1 (es) Anticuerpos contra el dominio 3 de la inmunoglobulina y de la mucina del linfocito t (tim3) y métodos de uso
EA201892068A1 (ru) Конъюгаты napi2b-нацеленное антитело-лекарственное средство и способы их применения